LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

Strona główna・Stock List・Maravai LifeSciences Holdings Inc (Class A)

Maravai LifeSciences Holdings Inc (Class A)

Closed

SectorHealthcare

4.41 -1.12

Buy Sell

Overview

Share price change

24h

Current

Min

4.38

Max

4.42

Key metrics
By Trading Economics
Income	36M -3.7M
Sales	16M 66M
EPS	0.01
Profit margin	-5.67
Employees	416
EBITDA	57M 15M

Recommendations
By TipRanks
Recommendations	Buy
12 Months Forecast	+9.55% upside

Dividends
By Dow Jones
Next Earnings	10 sie 2026

Market Stats
By TradingEconomics
Market Cap	133M 1.5B
Previous open	5.53
Previous close	4.41

News Sentiment

By Acuity

50%

151 / 345 Ranking in Healthcare

Maravai LifeSciences Holdings Inc (Class A) Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

24 maj 2026, 23:46 UTC

Market Talk

Pullback in Oil Prices Could Temper Inflation Expectations -- Market Talk

24 maj 2026, 23:45 UTC

Market Talk

Gold, Silver Rise on Hopes for U.S.-Iran Deal -- Market Talk

24 maj 2026, 23:42 UTC

Market Talk

Mineral Resources Bull More Positive Post Site Visit -- Market Talk

24 maj 2026, 23:34 UTC

Market Talk

Oil Falls Amid Prospects for Reopening of Strait of Hormuz -- Market Talk

24 maj 2026, 23:11 UTC

Market Talk

RBNZ Likely to Stand Pat But Watch for Dissent -- Market Talk

24 maj 2026, 22:26 UTC

Acquisitions, Mergers, Takeovers

Beach Energy: La Bella 2 Will No Longer Be Drilled as Part of Equinox Campaign

24 maj 2026, 22:25 UTC

Acquisitions, Mergers, Takeovers

Beach Energy: Implied Transaction Value of Around A$130 Million After Tax

24 maj 2026, 22:25 UTC

Acquisitions, Mergers, Takeovers

Beach Energy: Royalty Payments Likely to Total Around A$140 Million Based on Resource Booking

24 maj 2026, 22:24 UTC

Acquisitions, Mergers, Takeovers

Beach Energy to Get Production Royalty of A$3.75/GJ in Deal

24 maj 2026, 22:24 UTC

Acquisitions, Mergers, Takeovers

Beach Energy to Get A$70 Million Cash Proceeds When Deal Completes

24 maj 2026, 22:23 UTC

Acquisitions, Mergers, Takeovers

Beach Energy Says Deal Includes Artisan Natural-Gas Discovery

24 maj 2026, 22:23 UTC

Acquisitions, Mergers, Takeovers

Beach Energy Sells 60% Operated Interest in VIC/L35 Block in Otway Basin

24 maj 2026, 22:11 UTC

Market Talk

Oil Price Unlikely to Return to Pre-Conflict Levels This Year -- Market Talk

24 maj 2026, 22:04 UTC

Market Talk

Oil Price Likely Lower, Equities Higher on Iran Deal Talks Progress -- Market Talk

23 maj 2026, 08:20 UTC

Market Talk

Acquisitions, Mergers, Takeovers

Financial Services Roundup: Market Talk

23 maj 2026, 08:20 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

22 maj 2026, 21:10 UTC

Earnings

These Stocks Are Today's Movers: Dell, Apple, IBM, Estée Lauder, Futu, Rocket Lab, Workday, and More -- Barrons.com

22 maj 2026, 20:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

22 maj 2026, 20:50 UTC

Market Talk

Acquisitions, Mergers, Takeovers

Financial Services Roundup: Market Talk

22 maj 2026, 20:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

22 maj 2026, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

22 maj 2026, 19:47 UTC

Earnings

Nvidia Has a Plan to Get the Stock Moving Again -- Barrons.com

22 maj 2026, 19:17 UTC

Market Talk

U.S. Natural Gas Retreats As Weather Outlook Cools -- Market Talk

22 maj 2026, 19:10 UTC

Market Talk

Oil Futures Edge Up Ahead of U.S. Long Weekend -- Market Talk

22 maj 2026, 18:54 UTC

Market Talk

Global Equities Roundup: Market Talk

22 maj 2026, 18:54 UTC

Market Talk

Kroger Seen Narrowing Pricing Gap Versus Walmart -- Market Talk

22 maj 2026, 18:38 UTC

Market Talk

Canada's Population Slowdown Hits Demand for Consumer Companies -- Market Talk

22 maj 2026, 18:35 UTC

Acquisitions, Mergers, Takeovers

IMAX Might Be Exploring a Sale. Who Could Be Buying. -- Barrons.com

22 maj 2026, 18:09 UTC

Market Talk

Centralized Crypto Lending Slows in 1Q -- Market Talk

22 maj 2026, 17:58 UTC

Market Talk

U.S. Oil Rig Count Shows Signs of Picking Up -- Market Talk

Peer Comparison

Price change

Maravai LifeSciences Holdings Inc (Class A) Forecast

Price Target

By TipRanks

9.55% upside

12 Months Forecast

Average 4.82 USD 9.55%

High 6 USD

Low 3 USD

Based on 7 Wall Street analysts offering 12 month price targets forMaravai LifeSciences Holdings Inc (Class A) - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

7 ratings

Buy

Hold

Sell

Based on 7 analysts giving stock ratings to Maravai LifeSciences Holdings Inc (Class A) - Dist in the past 3 months.

Sentiment

By Acuity

151 / 345 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Maravai LifeSciences Holdings Inc (Class A)

Maravai LifeSciences Holdings, Inc., a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species. It operates in two segments, Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment manufactures and sells products for use in the fields of gene therapy, vaccines, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, and oligonucleotide building blocks, as well as custom enzyme development and manufacturing and CleanCap capping technology. The Biologics Safety Testing segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody, and assay development services. This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, viral clearance prediction kits, and custom services. The company serves biopharmaceutical companies, and other biopharmaceutical and life sciences research companies; and academic research institutions and in vitro diagnostics companies. The company was incorporated in 2020 and is headquartered in San Diego, California.